Sergio Emanuel Kaiser: Ruvonoflast and a New Anti-Inflammatory Strategy for Residual Cardiovascular Risk
Sergio Emanuel Kaiser, Coordinator at UERJ – Discipline of Clinical and Experimental Pathophysiology, Associate Professor of Medicine at Rio de Janeiro State University, shared a post on LinkedIn about a recent article by Kausik Ray, published in JACC, adding:
“EAS Congress 2026.
A new actionable pathway is tested in a phase 1 study by Kausik Ray and collaborators.
Rivonoplast, a potent inhibitor of NLRP3 inflamassome led to early and sustained reversible sCRP reduction compared to placebo.
Some pictures from his presentation depicted below.”
Title: Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk
Authors: Kausik K. Ray, Nicholas Clarke, Peter Thornton, Amy E. Miles, Zsofia Digby, Melanie J. Davies, Michelle Gorman, Bianca Mullen, Valérie Reader, Missy Magill, Hilary Johnstone, Cono Ariti, Naveed Sattar, Nikolaus Marx, Ann Marie Navar, Adrian F. Hernandez, Jyothis T. George, Alan P. Watt, Javed Butler, Paul M. Ridker
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 31, 2026, 05:35Does LDL Cholesterol Influence VTE Risk? – Ordo Fraterna Fibonacci
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients
-
Aug 31, 2026, 04:28Reza Hafidz Irawan։ Automated Antibody Titration With Erytra Eflexis
-
Aug 31, 2026, 04:17Safa Chenganath: Stenosis vs Thrombosis – Hemodialysis Vascular Access
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session